Closing the gap in care to combat the increasing rate of hepatitis C infections
Together, we can
make a difference.
HepConnect is a five-year, multi-million-dollar initiative aimed at addressing the increase in hepatitis C (HCV) infections. In partnership with local organizations, the initiative will develop and implement evidence-based solutions to meet the needs of people most affected by the opioid crisis.
To address growing HCV infection rates in greater Appalachia, HepConnect has three areas of focus:
Combatting the silent killer
within the opioid crisis.
Fueled by the nation’s growing opioid crisis, rates of HCV infections are rising.
In response, HepConnect is partnering with communities to provide support and innovative solutions.
View all stories
See the latest news
in the news
Why Greater Appalachia?
Going where the need
The largest increase in HCV infections occurs east of the Mississippi River, particularly in Appalachia and surrounding states.1 In central Appalachia, acute HCV infections rose 364% between 2006 and 2012.
In response to the intersecting opioid and HCV crises, Gilead has launched the HepConnect initiative, which supports community partnerships to combat the growing HCV infection rates in Indiana, Kentucky, North Carolina, Tennessee and West Virginia.